Page 14 - Revista científica HMVM ::: Hospital General de Agudos "Magdalena V. de Martínez"
P. 14
14 REVISTA CIENTÍFICA HMVM
12 Klijn, J. G., Setyono-Han, B., and Foekens, J. A. a National Cancer Institute of Canada Clinical Trials
Progesterone antagonists and progesterone receptor Group study. J.Clin.Oncol., 14: 2709-2712, 1996.
modulators in the treatment of breast cancer. Steroids, 16 Klijn, J. G., Setyono-Han, B., and Foekens, J. A.
65: 825-830, 2000 Progesterone antagonists and progesterone receptor
modulators in the treatment of breast cancer. Steroids,
13 Romieu, G., Maudelonde, T., Ulmann, A., Pujol, H., 65: 825-830, 2000.
Grenier, J., Cavalie, G., Khalaf, S., and Rochefort, H. 17 Beck, C. A., Weigel, N. L., Moyer, M. L., Nordeen, S.
The antiprogestin RU486 in advanced breast cancer: K., and Edwards, D. P. The progesterone antagonist
preliminary clinical trial. Bull.Cancer, 74: 455-461, RU486 acquires agonist activity upon stimulation of
1987. cAMP signaling pathways. Proc.Natl.Acad.Sci.U.S.A.,
90: 4441-4445, 1993
14 Klijn, J. G., de Jong, F. H., Bakker, G. H., Lamberts, 18 Helguero, L. A., Viegas, M., Asaithamby, A., Shyamala,
S. W., Rodenburg, C. J., and Alexieva-Figusch, J. G., Lanari, C., and Molinolo, A. A. Progesterone
Antiprogestins, a new form of endocrine therapy for receptor expression in medroxyprogesterone acetate-
human breast cancer. Cancer Res., 49: 2851-2856, induced murine mammary carcinomas and response
1989. to endocrine treatment. Breast Cancer Res.Treat.,
79: 379-390, 2003.
15 Perrault, D., Eisenhauer, E. A., Pritchard, K. I., Panasci,
L., Norris, B., Vandenberg, T., and Fisher, B. Phase II
study of the progesterone antagonist mifepristone in
patients with untreated metastatic breast carcinoma:
